Pharmacological replacement with GLP-1 receptor agonists in patients with Type 2 diabetes represents an attractive strategy to improve metabolic control, particularly as we aim for near-normal glycaemia, with less risk of hypoglycaemia and no weight gain or, ideally, weight loss. Here, GLP1R is linked to type 2 diabetes mellitus.